Wednesday, February 1, 2017

CRH Medical - Chart of the Day

CRH Medical (CRHM) is the Barchart Chart of the Day.  The medical instrument company has a Trend Spotter buy signal, a Weighted Alpha of 138.34+ and gained 140.94% in the last month.

The Chart of the Day belongs to CRH Medical (CRHM).  I found the medical instrument stock by using Barchart to sort today's All Time High list first for the highest Weighted Alpha, then again for technical buy signals of 80% or more.  Since the Trend Spotter signaled a buy on 1/4 the stock gained 7.59%.  The stock is a pure momentum play as there is not enough other info on which to base further conclusions.

CRH Medical Corporation offers products and services to physicians for the treatment of gastrointestinal diseases primarily in the United States. The company provides the CRH O'Regan System, a single use, disposable and hemorrhoid banding technology for treating hemorrhoid grades I - IV. It distributes the CRH O'Regan System, treatment protocols, operational and marketing expertise as a complete, turnkey package directly to physicians. The company utilizes Web-based platform to connect doctors with patients as well as educating its install base of physicians. It also offers anesthesia services. CRH Medical Corporation is headquartered in Vancouver, Canada.

The status of Barchart's Opinion trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the web site when you read this report.

Barchart technical indicators:

  • 96% technical buy signals
  • Trend Spotter buy signal
  • Above its 20, 50 and 100 day moving averages
  • 10 new highs and up 18.86% in the last month
  • Relative Strength Index 63.46%
  • Technical support level at 6.12
  • Recently traded at 6.25 with a 50 day moving average of 5.69
Fundamental factors:
  • Market Cap $440 million
  • Analysts estimated a 25.00% increase in earnings next year
  • Wall STreet analysts issued 4 strong buy recommendations but little else on the stock

No comments:

Post a Comment